International Journal of Hematology

DOI: 10.1007/s12185-016-2166-0 Pages: 658-667

Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era

1. Kyoto Prefectural University of Medicine, Division of Hematology and Oncology, Department of Medicine

2. Matsushita Memorial Hospital, Department of Hematology

3. Japanese Red Cross Kyoto Daini Hospital, Department of Hematology

4. Kyoto Prefectural University of Medicine, Department of Surgical Pathology

Correspondence to:
Junya Kuroda
Email: junkuro@koto.kpu-m.ac.jp

Close

Abstract

Disease-specific cytogenetic abnormalities involving BCL2 gene rearrangement frequently co-exist with other cytogenetic abnormalities, contributing to disease progression in follicular lymphoma (FL). In the present study, we retrospectively investigated the prognostic impact of BCL2-unrelated cytogenetic abnormalities in FL. Of 139 consecutively diagnosed patients with FL at two independent institutes, metaphase spreads of tumor cells were obtained for use in G-banding analysis in 77 patients. The recurrent additional cytogenetic abnormalities included chromosome gains +5 (n = 8), +7 (n = 16), +12 (n = 10), and +X (n = 12), and losses −8 (n = 7), −13 (n = 12) −15 (n = 7), and 6q− (n = 7). While −15 was associated with shorter progression-free survival (PFS) in all 77 analyzed patients with evaluable G-banding results (p = 0.04), this negative impact was not evident in 42 patients treated using an R-CHOP-like regimen as first-line treatment. By contrast, 6q− was predictive for shorter PFS in patients who were initially treated with R-CHOP-like regimens without maintenance therapy (p < 0.01), while this negative impact was not evident in all 77 patients with evaluable G-banding results. These results suggest the presence of a molecular region in chromosome 6q that is responsible for the shorter PFS following R-CHOP-like chemotherapy.

To access the full text, please Sign in

If you have institutional access, please click here

  • Google+
  • LinkedIn
Share the Knowledge